Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

232 FLUOROURACIL
Rectal mucosal ulceration
(2006): Navarro M+, Int J Radiat Oncol Biol Phys 66(1), 201 (8%)
Stomatitis (>10%)
(2007): Papadeas E+, Eur J Oncol 11(1), 60
(2005): D’Andre S+, Clin Colorectal Cancer 4(5), 325 (17%)
(2003): Rossi A+, Oncology 64(4), 353
(2003): Saini A+, Br J Cancer 88(12), 1859
(2003): Tebbutt NC+, Br J Cancer 88(10), 1510
(2002): Bonneterre J+, Br J Cancer 87(11), 1210 (40%) (with
vinorelbine)
(2002): Ito A+, Gan To Kagaku Ryoho 29(4), 563
(2002): McCollum AD+, J Natl Cancer Inst 94(15), 1160
(2002): Sloan JA+, J Clin Oncol 20(6), 1491
(2002): Ueno H+, Cancer Chemother Pharmacol 49(2), 155
Tongue pigmentation
(2001): Schmid-Wendtner M-H+, Lancet 358, 1575 (passim)
Hair
Hair – alopecia (>10%)
(2003): Saini A+, Br J Cancer 88(12), 1859
(2002): Sloan JA+, J Clin Oncol 20(6), 1491
(2001): Madnani N, Mumbai, India (from Internet) (observation)
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin
Blackwell, Oxford, 193 (passim)
Nails
Nails – onycholysis
Nails – periungual granuloma
(2006): Curr N+, Australas J Dermatol 47(2), 130
Nails – pigmentation (